Status:

COMPLETED

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Lead Sponsor:

University of Michigan Rogel Cancer Center

Collaborating Sponsors:

Janssen Scientific Affairs, LLC

AstraZeneca

Conditions:

Sarcoma

Sarcoma Metastatic

Eligibility:

All Genders

16+ years

Phase:

PHASE2

Brief Summary

This phase II trial studies how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in chemothe...

Eligibility Criteria

Inclusion

  • Key Inclusion Criteria
  • Age ≥ 16 years
  • Advanced unresectable or metastatic sarcoma
  • Cohort 1: Leiomyosarcoma (LMS)/Liposarcoma (LPS)
  • Cohort 2: Other sarcoma histologies (excluding gastrointestinal stromal tumors)
  • Received at least 1 prior standard chemotherapy. For cohort 1 patients, this must have included a prior anthracycline.
  • Measurable disease by RECIST 1.1
  • Adequate hematologic, renal, hepatic function
  • Adequate creatine phosphokinase
  • ECOG performance status ≤ 1
  • Left ventricular ejection fraction (LVEF) \>= institutional lower limit of normal (LLN)
  • Women of childbearing potential and men must agree to use adequate contraception from signing informed consent to at least 6 months (females) and 5 months (men) after study drug treatment
  • Key Exclusion Criteria
  • Prior therapy with PARP inhibitor, including olaparib
  • Prior therapy with trabectedin
  • Additional active malignancy or treatment for alternative cancer (excluding non-melanoma skin cancer) requiring treatment within the past two years
  • Pregnant or breastfeeding women
  • Known hypersensitivity to trabectedin or olaparib
  • Other exclusions per protocol

Exclusion

    Key Trial Info

    Start Date :

    March 17 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 26 2024

    Estimated Enrollment :

    29 Patients enrolled

    Trial Details

    Trial ID

    NCT04076579

    Start Date

    March 17 2020

    End Date

    September 26 2024

    Last Update

    August 29 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, United States, 48109